Table 1 Study characteristics of the included studies in the systemic review/meta-analysis
Authors/years | Country | Sample size | Type of study | Mean age | Diagnosis of alveolar osteitis | Interventions | Outcomes | Results | ||
|---|---|---|---|---|---|---|---|---|---|---|
Experimental groups | Control group | Experimental | Control | |||||||
Torres-Lagares et al., 2010 [18] | Spain | expermental:24 Control: 14 | Randomized, double-blinded study | Average age 32 (ranged, 18 to 57) | Blum’s criteria | 0.2% Chlorehixidine (CHX) gel | Gel placebo | 1 case of alveolar osteitis | 4 cases of alveolar osteitis | The difference was not statistically Significant (p = 0.402). |
Babar et al., 2012 [24] | Pakistan | Experimenta: 50 Control:50 | Randomized controlled trials | 29 (+6 age) (Range 18 to 40 years) | Blum’s criteria | 0.2% CHX gel + (ibuprofen 400 mg) | No treatment + ibuprofen 400 mg) | 4 cases with alveolar osteitis | 14 cases with alveolar osteitis | A single application of CHX gel was effective in reducing frequency of alveolar osteitis following mandibular third molar surgery. |
Khan et al., 2015 [29] | USA | Experimental: 128 Contro:125 | Double-blinded Randomized clinical trial | 36.65 (±11 year) | Blum’s criteria Visual Analog Scale (VAS), | 0.2%CHX gel | Placebo gel | 7 cases with alveolar osteitis | 23 cases with alveolar osteitis | Therefore, application of CHX in generalized Is recommended. |
Freudenthal, 2015 [23] | Sweden | expermental48 Control:47 | Double-blinded randomized | 19 to 65 years: age range 33 years (SD, 10.3 years) | Blum’s criteria | 0.2% CHX gel | Placebo gel | 11 cases with alveolar osteitis | 9 cases with alveolar osteitis | Did not verify that application of CHX gel improves healing |
Passi and Shekhar, 2013 [25] | Lucknow, U.P | expermental:40 Control:40 | Clinical trial | NA | Blum’s criteria | 0.2%CHX gel Amoxacilline/clavulanic acid, Metronidazole | 0.9% normal saline | 1 case with alveolar osteitis | 3 cases with alveolar osteitis | Reduce the incidence of alveolar osteitis after the extraction of impacted mandibular third molars by approximately30-40%. |
Shaban et al., 2014 [21] | Iran | expermental: 41 Control:41 | Double-blind Clinical Trial | 24.15 ± 5.02 Age range : 18–35 | Blum’s criteria | 0.2% CHX gel | No | 2 cases with alveolar osteitis | 9 cases with alveolar osteitis | The frequency of alveolar osteitis was significantly lower in sockets receiving the CHX gel in comparison to control sockets (RR = 0.22, 95%CI:0.06–0.71) |
Rubio-Palau et al., 2015 [19] | Spain | expermenta:80 Control:80 | Double-blind Clinical Trial | 25.04 mean age | Blum’s criteria | 0.2% CHX gel | Bioadhesive placebo | 14 cases with alveolar osteitis | 18 cases with alveolar osteitis | Reduced the frequency of AO by 22.22% compared to the control group |
Ahmedi et al., 2014 [22] | Kosovo | expermental:25 Control:25 | A randomized Split-mouth-design | Blum’s criteria | 1% CHX gel | Saline solution | 1 case with alveolar osteitis | 7 cases with alveolar osteitis | The application of CHX gel 1% may significantly reduce the incidence of DS following third molar extraction. | |
Inamdar et al., 2015 [26] | India | expermental:20 Control:10 | Comparative Randomized Prospective Study | Blum’s Criteria | 10 patients receive CHX gel; 10 patients revive ornidazole gel | No treatment | 1 case with alveolar osteitis | 2 cases with alveolar osteitis | The incidence of avolar osteitis is significantly less on placement of CHX gel | |
Haraji et al., 2013 [20] | Iran | Expermental : 40 Control:40 | Double-blinded split-mouth randomized study | 18–45 years (Age range) 21.6 ± 2.5 years | Blum’s standardized criteria | 0.2% CHX gel | Placebo Gel | 9 cases with alveolar osteitis | 26 cases with alveolar osteitis | Single-dose intra-alveolar application of CHX gel can reduce dry socket incidence. |